Real-world study on the use of pegylated interferon alpha-2a for treatment of mycosis fungoides/S ézary syndrome using Time to Next Treatment as a measure of clinical benefit: An EORTC CLTG study

CONCLUSIONS: PEG IFN α-2a for MF/SS showed ORR of 53%, TTNT of 9.2 months, superiority of combination regimens in comparison to monotherapy and doses of 180 mcg/weekly related to higher ORR.PMID:38596857 | DOI:10.1093/bjd/ljae152

Source: The British Journal of Dermatology - April 10, 2024 Category: Dermatology Authors: Keila Mitsunaga Martine Bagot Caroline Ram-Wolff Emmanuella Guenova Christina von Gugelberg Emmilia Hodak Iris Amitay-Laish Evangelia Papadavid Constanze Jonak Stefanie Porkert Julia Scarisbrick Rona Applewaite Marie Beylot-Barry Jan Nicolay Pietro Quagli Source Type: research